ARK Holds 5.54% Of Prime Medicine Without A Bid To Influence Control

The investment manager reported more than 10 million shares in the developer of DNA-editing medicines.

Share
ARK Holds 5.54% Of Prime Medicine Without A Bid To Influence Control

ARK Investment Management reported Friday that it held a 5.54% stake in Prime Medicine, which develops genetic medicines that rewrite DNA to correct disease-causing changes. Its SEC passive ownership disclosure certified that the shares were held for ordinary business purposes without an intent to change or influence control.

One Holding, Shared Reporting

ARK reported 10,043,508 common shares as of September 30, 2026. Catherine D. Wood, the investment manager's chief executive officer and chief investment officer, was a joint reporting person for the same holding.

ARK had sole voting power over those shares; Wood reported shared voting power over the same shares. The ownership figures describe the same position, not separate holdings to be added together.

ARK's exchange-traded funds hold concentrated positions in small and midsize companies, frequently exceeding the 5% ownership threshold. That pattern has produced about 170 ownership schedules over two years.

PRME shares soared about 12% to $4.35 in Friday trading versus the prior close. Prime Medicine's market value was $706 million in Friday trading.

DNA Editing And Licensing Revenue

Prime Medicine combines its own treatment-development programs with research and licensing partnerships. Its Prime Editing technology is designed to correct disease-causing DNA changes.

The company's wholly owned programs target liver diseases, including Wilson disease and alpha-1 antitrypsin deficiency. It also conducts cystic fibrosis research and has a clinical program for chronic granulomatous disease.

Bristol-Myers Squibb licenses Prime Medicine's technology to develop treatments using immune cells edited outside the body. The collaboration, signed in September 2024, brought Prime Medicine a $55 million upfront payment.

The Cystic Fibrosis Foundation provides development funding for the company's cystic fibrosis work.

Sources

More on Prime Medicine

All Prime Medicine (PRME) coverage →